The Royal Adelaide Hospital, colloquially known by its initials or pronounced as "the Rah", is South Australia's largest hospital, owned by the state government as part of Australia's public health care system.

There are 800 beds in Royal Adelaide Hospital; Hepatology.

During the past decade, Royal Adelaide Hospital; Hepatology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Royal Adelaide Hospital; Hepatology" are "Malignant Melanoma" (1 trials) and "Melanoma" (1 trials). Many other conditions were trialed in "Royal Adelaide Hospital; Hepatology" in a lesser frequency.

Most popular intervention types in "Royal Adelaide Hospital; Hepatology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Vemurafenib" (2 trials) and "Cobimetinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Royal Adelaide Hospital; Hepatology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Royal Adelaide Hospital; Hepatology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Royal Adelaide Hospital; Hepatology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Royal Adelaide Hospital; Hepatology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".